© 2000 American Heart Association, Inc.
Review |
The Preconditioning Phenomenon
A Tool for the Scientist or a Clinical Reality?
From The Hatter Institute, Department of Academic and Clinical Cardiology, University College London Hospitals and Medical School, London, UK.
Correspondence to D.M. Yellon, The Hatter Institute, Department of Academic and Clinical Cardiology, University College Hospital, Grafton Way, London WC1E 6DB, UK. E-mail s.bush-cavell{at}ucl.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
Abstract—The possibility that an innate mechanism of myocardial protection might be inducible in the human heart has generated considerable excitement and enthusiastic research. The potential to enhance myocardial resistance to ischemic injury in patients suffering the consequences of coronary artery disease has led to studies with more direct clinical relevance. However, in common with many other areas of clinical interest based on advances in basic scientific understanding, early enthusiasm may be disproportionate to ultimate therapeutic significance. There can be little doubt that our understanding of the mechanisms underlying the pathogenesis of ischemia-reperfusion injury has been enhanced significantly by the plethora of research stimulated by interest in endogenous myocardial protection. Direct extrapolation of observations in the laboratory to the cardiology clinic or operating theater is tempting but should be avoided. The results of recent clinical experiments that suggest that preconditioning can protect against ischemia, although encouraging, should be interpreted cautiously, with particular attention to the limitations of the end points available. A reasoned evaluation of recent research should prevent unrealistic expectations and allow improved design of future trials so that this potent adaptive phenomenon can be exploited to its maximum potential.
Key Words: preconditioning • unstable angina • myocardial infarction • coronary angioplasty • coronary bypass surgery
|
Introduction |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
The observation that serial brief episodes of ischemia with intervening reperfusion did not lead to progressive depletion of high-energy phosphates in the canine myocardium1 led the same group of investigators to examine the response of hearts "preconditioned" with short bursts of sublethal ischemia to a sustained ischemic insult.2 Their finding that the onset of infarction was delayed in pretreated hearts, with a significant reduction in ultimate myocardial infarct size, resulted in recognition of the concept of ischemic preconditioning, with a proposal that the mechanism responsible involved a slowing of consumption of high-energy phosphates during the prolonged ischemic insult. Since then, this marked limitation of infarction induced by antecedent brief periods of ischemia has been demonstrated in every animal species studied.3 Subsequent studies have suggested that protection against other end points of injury such as myocardial stunning and reperfusion arrhythmias may also be possible.4 5 6 Characterization of the time frame of protection has demonstrated a biphasic pattern with an initial ("classical" or early) powerful phase that lasts 1 to 2 hours after the preconditioning stimulus and a subsequent "second window" 12 to 72 hours later.7 8 It is also important to note that in experimental studies ischemic preconditioning has been found to limit infarction when the duration of the sustained ischemic insult is
30 to 90 minutes, but is ineffective when
this period is extended to 3 hours.3 This temporal
limitation of ischemic preconditioning implies that the
protection is only observed when prolonged ischemia is followed
by timely reperfusion. The potential for clinical application of such a powerful protective phenomenon has generated enormous interest in identification of the underlying intracellular signaling pathways, with the ultimate aim of pharmacologically exploiting these mechanisms to develop therapeutic strategies that can enhance myocardial tolerance to ischemia-reperfusion injury in patients with coronary artery disease. Extensive research over the past 15 years has gone a long way in elucidating a number of membrane receptor–linked cellular triggers, intracellular signaling cascades, and potential cytoprotective end-effector proteins that may be involved in mediating the protective effects of ischemic preconditioning.3 However, the application of these findings to the clinical setting depends primarily on proof of safety and efficacy when compared with other strategies of myocardial protection and secondarily on identification of well-defined cohorts of patients who stand to benefit from pretreatment with such cardioprotective agents. Several important issues need to be addressed and are discussed below.
|
Does Preconditioning Occur in the Human Heart? |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
Ethical considerations restrict the nature of experimental work on the human heart and thereby render the evidence indirect. Numerous approaches have, to some extent, circumvented this problem. Studies in cells derived from isolated human ventricular myocytes9 10 and in isolated atrial trabeculae obtained at the time of cardiac surgery11 suggest that protection can be induced in vitro using metabolic and functional end points, respectively. Moreover, using the same in vitro models, it has been demonstrated that the mechanisms of protection in human tissue closely resemble those observed in many animal species, namely, the involvement of adenosine as an important trigger, protein kinase C as an intermediate intracellular messenger, and the ATP-dependent K+ (KATP) channel as a potential end-effector protein.12 13 14 15
In the clinical setting, there is some evidence to suggest that preconditioning may occur naturally in patients with coronary artery disease. Patients suffering angina before a myocardial infarction (MI) have a better in-hospital prognosis; a reduced incidence of cardiogenic shock, congestive cardiac failure, and life-threatening ventricular arrhythmias associated with reperfusion; and smaller infarcts as assessed by release of cardiac enzymes.16 17 18 19 Follow-up studies have suggested that in patients with preinfarction angina, long-term survival is also improved as compared with patients who are asymptomatic before infarction.20 21 Whether the protection conferred to these patients as a result of their preceding ischemic symptoms represents a form of myocardial adaptation similar to ischemic preconditioning remains a subject of debate.22 On the one hand, the issue of enhanced collateral development in patients with preceding anginal symptoms remains unresolved. Another equally attractive hypothesis, although not mutually exclusive from the mechanisms underlying ischemic preconditioning, is facilitation of more rapid reperfusion of the infarct-related artery after thrombolysis in patients with preinfarction angina.20 23 This hypothesis is based on the known inhibitory effects of adenosine, released during the brief periods of preinfarction ischemia, on platelet aggregation after activation of A2 receptors on platelet membranes, which has been suggested to modify thrombus formation and thereby promote earlier reperfusion after thrombolysis.24 Indeed, in anesthetized open-chest dogs, brief periods of ischemia before a long ischemic insult attenuates platelet-mediated thrombosis and improves vessel patency, and this effect is abolished by inhibition of adenosine receptors.25
The phenomenon of "warm-up angina," in which patients complain that their anginal symptoms are worse in the morning but improve during the course of the day, has been the subject of research over the past few years.26 27 This work has provided evidence for increased efficiency of myocardial metabolism, in terms of reduced oxygen consumption at a given workload and a reduction in anginal symptoms and ST-segment changes, during a second period of either exercise or angina resulting from pacing-induced tachycardia. These favorable changes were not accompanied by recruitment of collateral vessels, as evidenced by similar coronary and great cardiac vein blood flow measurements. Similarly, a reduction in electrocardiographic evidence of silent ischemia during successive periods of exercise has been demonstrated.28 A recent study suggests that the degree of myocardial stunning after exercise-induced myocardial ischemia may also be attenuated if the patient had performed a preceding period of exercise 30 minutes earlier.29 Studies investigating the temporal profile of warm-up angina have demonstrated that the duration of this phenomenon is 1 to 2 hours after the first period of exercise, a time course that closely parallels that of classic ischemic preconditioning.30 31 Moreover, we have recently shown that in addition to immediate protection, patients with stable angina have improved exercise tolerance 24 hours after a period of exercise-induced myocardial ischemia, a finding that may represent delayed preconditioning.32 However, a recent study using a similar study protocol failed to show enhanced exercise tolerance 24 hours after a period of exercise, thereby arguing against delayed protection in this model.33 The reasons for the differences between these studies is not immediately obvious and requires further investigation.
These findings suggest that the warm-up phenomenon is at least partly due to metabolic adaptation of myocardium, which induces tolerance to subsequent ischemia, a process that closely resembles ischemic preconditioning. However, studies that have examined the cellular mechanisms mediating warm-up angina do not fully support this hypothesis. For instance, inhibition of adenosine receptors before exercise fails to abolish the warm-up phenomenon.34 35 Furthermore, investigation into the role of KATP channels in mediating this form of myocardial adaptation has provided conflicting results.36 37 It is therefore not clear at this point whether the adaptation observed during repeated exercise is a representation of the preconditioning phenomenon or whether other mechanisms are involved. Furthermore, despite attempts by some investigators, a major role for recruitment of collateral vessels contributing to this phenomenon has not been ruled out.
Myocardial Adaptation During Revascularization Procedures
Percutaneous transluminal coronary
angioplasty (PTCA) provides a unique opportunity to study the response
of the human myocardium to brief periods of controlled
ischemia and reperfusion. The procedure usually involves
repeated intracoronary balloon inflations with intervening
periods of perfusion, and in theory the first period of
ischemia may enhance the myocardial tolerance to subsequent
balloon inflations via classic ischemic preconditioning.
Several recent studies have addressed this issue using various indices
of myocardial ischemia including clinical,
electrocardiographic, metabolic, and
hemodynamic measurements. Most of these studies have
shown that if the duration of the first balloon inflation is longer
than a "threshold" of 60 to 90 seconds, all indicators of
myocardial ischemia, including chest pain severity,
abnormalities of left ventricular regional wall motion,
ST-segment elevation, QT dispersion, ventricular ectopic
activity, lactate production, and release of myocardial markers
such as CKMB, are attenuated during subsequent balloon
inflations, which provides evidence for myocardial adaptation induced
by the first period of ischemia.38 39 40 41 42 43 As with
many studies of ischemic preconditioning in humans, a major
confounding factor during successive balloon inflations in PTCA studies
is the acute recruitment of collateral vessels. However, studies that
have controlled for this effect by angiographic grading of the
collateral vessels39 ; measurement of cardiac vein
flow38 ; changes in blood flow velocity in the
contralateral coronary artery44 ; and, more
accurately, by assessment of intracoronary pressure-derived
collateral flow index during successive balloon
inflations45 have shown that although collateral
recruitment occurs in some patients, it cannot fully explain the
myocardial adaptation observed during repeated balloon inflations.
Investigation into the mechanisms underlying this rapid protection of the myocardium during PTCA has provided further support for a preconditioning-like effect. Blockade of KATP channels with oral glibenclamide before angioplasty abolishes the reduction in ischemic indices observed during subsequent balloon inflations, which implies a role for these channels in mediating this form of adaptation.46 This finding is supported by the observation that opening of these channels with nicorandil reduces the electrocardiographic indices of ischemia during coronary angioplasty.47 Furthermore, an important role has been demonstrated for adenosine in mediating myocardial adaptation during coronary angioplasty. Inhibition of adenosine receptors by bamiphylline48 or aminophylline49 abolishes myocardial adaptation during the second balloon inflation. Conversely, intracoronary infusion of adenosine before PTCA, independent of its vasodilatory effect, attenuates ischemic indices during the first balloon inflation.50 Two other recent reports have suggested a role for both opioid51 and bradykinin52 receptors in mediating myocardial adaptation during PTCA. These studies provide further evidence that myocardial tolerance to further ischemic episodes can be induced by preceding brief periods of ischemia and that this tolerance may be mediated by the same mechanisms as those involved in ischemic preconditioning in animal models.
However, recent experimental evidence has provided grounds for caution when interpreting the results of these PTCA studies, which have mostly used ST-segment elevation on the surface or intracoronary ECG as an end point reflecting the degree of myocardial ischemia, and its attenuation during successive balloon inflations as an indicator of enhanced myocardial resistance to ischemia. Although this assumption was supported by earlier experimental studies of repeated coronary artery occlusion in collateral-deficient pig and rabbit hearts,53 54 a recent study clearly indicates a dissociation between ST-segment changes on the ECG and myocardial protection in terms of infarct limitation.55 The finding of these authors, that the changes in ST-segment voltage during coronary artery occlusion may merely represent an epiphenomenon distinct from the cardioprotective effect of ischemic preconditioning, is particularly pertinent when evaluating or designing mechanistic studies using pharmacological agents to mimic or abolish the cellular signaling mechanisms of ischemic preconditioning. It is imperative that the influence of these pharmacological tools on the sarcolemmal KATP channels, which are thought to modulate ECG voltages, is clearly distinguished from their effect on the mitochondrial KATP channels, which have been proposed as a mediator of cardioprotection.56
Possibly the most direct evidence for preconditioning in humans comes from studies that have examined the effect of preconditioning protocols in patients undergoing cardiac surgery in which resistance to global ischemia is assessed, a setting that is not confounded by changes in collateral recruitment. In this respect, we reported a prospective study examining the effects of a preconditioning protocol of 2 cycles of 3 minutes of global ischemia (induced by intermittently cross-clamping the aorta and pacing the heart at 90 bpm) followed by 2 minutes of reperfusion before a 10-minute period of global ischemia and ventricular fibrillation.57 Patients subjected to this protocol had better preservation of ATP levels in myocardial biopsies during a subsequent 10-minute global ischemic period. These metabolic changes were almost identical to those seen in dogs by Reimer et al.1 However, total myocardial ATP content may not reflect local turnover within subcellular compartments and certainly does not provide information about the efficiency of cellular metabolism in terms of ATP requirements. In a more recent study involving a larger group of patients, serum levels of troponin T were used as an indicator of myocardial cell necrosis. Using this end point, patients subjected to the same preconditioning protocol suffered less necrosis as determined by release of troponin T.58 Of considerable interest, however, was the finding that the ATP levels did not differ between preconditioned and control groups. This emphasizes the need for multiple end points to be used, especially in studies in which small differences in myocardial viability without overt clinical effects are expected.
On the other hand, studies that have used other cardioprotective strategies during the prolonged period of ischemia, such as hypothermia or cardioplegia, have not consistently demonstrated additional protection by ischemic preconditioning. For instance, the use of similar preconditioning protocols of one 3-minute episode of aortic cross-clamping before the onset of cardioplegic arrest failed to show any beneficial effects compared with the control group; in fact, the preconditioned group of patients had more creatine kinase release compared with case-matched controls.59 Similarly negative results have been reported by another group.60 These divergent results have led to the hypothesis that in the setting of coronary artery bypass surgery, the additional protection conferred by ischemic preconditioning may only be demonstrable in cases in which a potential for suboptimal myocardial protection increases the risk of perioperative infarction.61 However, this hypothesis is not supported by recent studies that indicate improved myocardial preservation by ischemic preconditioning during coronary bypass or valve surgery despite optimal protection with hypothermia and cardioplegia.62 63 Resolution of these discrepancies is obviously required before brief antecedent ischemia can be advocated as a means of prophylactic therapy.
|
Which Patients May Benefit? |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
Although it would appear from the evidence outlined above that the human myocardium is amenable to preconditioning, this does not imply that clinical benefit will automatically follow. Prompt reperfusion will always remain the most effective method of infarct size limitation and is therefore the most important determinant of prognosis. Preconditioning, by virtue of delaying myocardial necrosis, prolongs the time window during which revascularization therapies can be effectively instituted. However, the use of brief antecedent ischemia as a means of prophylactic induction of this protection is not desirable or feasible in most circumstances. On the other hand, the use of pharmacological agents capable of mimicking the protective effects of preconditioning, in lieu of brief ischemia, may provide a more benign approach for eliciting cardioprotection. However, even with the development of pharmacological agents that may be capable of mimicking the protection, timing of administration remains a critical limiting factor.
First, deployment of pharmacological preconditioning strategies necessitates pretreatment; the pathophysiology of the preconditioning phenomenon dictates that the myocardium must be preconditioned before the onset of a potentially lethal ischemic insult. This depends on identification of a relatively well-defined cohort of patients who are at high risk of acute coronary occlusion and stand to benefit from preconditioning or from pretreatment with agents that trigger or augment myocardial preconditioning.
The acute coronary syndromes (ACSs) comprise a spectrum of pathophysiological conditions spanning unstable angina, non–ST-elevation MI, and acute ST-elevation MI. In patients with acute MI with persistent ST elevation, early reperfusion to re-establish epicardial blood flow is well established as the standard of care, be it with early fibrinolytic therapy or, where the facilities and expertise are available, with primary angioplasty.64 As far as pharmacological preconditioning strategies are concerned, these patients are unlikely to benefit from such treatment, and their management should focus on early restoration of coronary artery patency and potential strategies to minimize reperfusion injury. On the other hand, non–ST-elevation ACSs, including unstable angina and non–Q-wave MI, mark the transition from stable coronary artery disease to an unstable state and constitute the leading cause of hospital admission in patients with coronary artery disease. This group of patients is at a high risk of progression to acute coronary occlusion, and >10% die or suffer a MI (or reinfarction) within 6 months, with about one half of these events occurring during the acute early phase.65
This cohort of patients with non–ST-elevation ACS forms a reasonably well-defined high-risk group that might benefit from pretreatment with agents that trigger or augment myocardial preconditioning over a period of several days or weeks and could therefore effectively maintain the myocardium in a protected or "preconditioned" state. A number of these patients who suffer a MI after unstable symptoms may be "naturally" preconditioned by their preceding ischemic episodes. Recent evidence, however, suggests that this natural protection is limited to those patients in whom the episodes of preinfarction angina occur during a narrow time window in relation to the infarct.20 21
Second, even when prior treatment with the pharmacological preconditioning agent is feasible, the duration of the protection afforded is limited. The temporal profile of the protective effects of preconditioning in humans is unknown but, according to experimental evidence in laboratory animals, it is unlikely to exceed 48 to 72 hours.66 67 Therefore, unless the onset of an ischemic event can be predicted with accuracy, repeated dosing with the potential preconditioning drug will be necessary in these high-risk patients to maintain the preconditioned state. Early experimental evidence suggested that the protective effects of classic ischemic preconditioning are lost after prolonged periods of repetitive ischemia68 or chronic pharmacological preconditioning with selective adenosine A1 agonists.69 However, recent encouraging evidence indicates that tachyphylaxis could be overcome by exploiting the prolonged time course of the second window of protection. Intermittent treatment of conscious rabbits with an optimal dosing regimen of pharmacological preconditioning with selective adenosine A1 receptor agonists maintains the animals in a preconditioned state over a period of several days and results in a significant reduction in infarct size.70 71
Very few studies have evaluated a protective role for pharmacological preconditioning strategies in patients with non–ST-elevation ACS. In this regard, a recent report suggests that opening of KATP channels with nicorandil, in addition to standard aggressive medical therapy for unstable angina, results in a significant reduction in the incidence of myocardial ischemic episodes and tachyarrhythmias.72 This may purely represent an anti-ischemic effect due to the vasodilatory properties of nicorandil. However, because the patients in this study were already on maximal antianginal therapy, and in particular a significant proportion were treated with intravenous or oral nitrates, it is possible that the protection observed in the nicorandil group, be it only using soft end points of myocardial injury, may at least partially be due to a preconditioning-like effect.73 These encouraging findings, coupled with very recent experimental evidence indicating that nicorandil specifically activates the mitochondrial rather than the sarcolemmal KATP channels in rabbit ventricular myocytes,74 provide a promising new approach to myocardial protection in patients with unstable angina.
Although the conditions of the majority of patients with
non–ST-elevation ACS will stabilize with effective
anti-ischemic medications, 50% of such patients will
require coronary angiography and
revascularization because of failure of medical
therapy assessed by recurrence of ischemic symptoms at
rest or demonstration of provokable ischemia during stress
testing.65 The optimal timing of
revascularization procedures in patients with ACS
is under debate, although recent evidence points to the benefit of
early intervention.75 However, the complication rate
associated with revascularization procedures in
unstable patients is appreciably higher than that in patients with
stable coronary artery disease. For example, emergency PTCA in
patients with refractory unstable angina is associated with a
periprocedural mortality rate of 1% to 3% and nonfatal infarction
occurs in a further 6% to 10%, with a need for emergency surgery in
up to 12%.65 76 The potential for and the time course of
any protection conferred by preceding anginal episodes in this
situation is not known, although some evidence suggests that unstable
symptoms occurring in the 6 to 12 hours before PTCA may have a
preconditioning-like effect.77 Conversely, the
Thrombolysis in Myocardial Ischemia (TIMI) IIIB
study suggested that emergency PTCA performed within 24 hours of
enrollment was the most powerful predictor of periprocedural death and
MI.76 Although the risk associated with the procedure
diminishes if a patient is allowed to "cool off" and the plaque is
at least partly healed, this longer waiting period carries the risk of
progression to MI and death. These patients may therefore have the most
to benefit from pretreatment with agents that mimic preconditioning or
augment the protection afforded by naturally occurring ischemic
preconditioning, thereby reducing the degree of myocardial injury in
the event of periprocedural complications associated with PTCA. At the
other end of the spectrum are patients with stable angina undergoing
elective PTCA, who have a relatively low risk of complete
coronary artery occlusion and MI (<5%). However, as more
high-risk procedures are performed, and considering the potential
benefits associated with this potent mode of cardioprotection, it is
possible that application of pharmacological preconditioning agents may
find a place routinely before elective angioplasty.
Similar complications may arise during cardiac surgery. In patients with unstable angina undergoing coronary artery bypass grafting (CABG), perioperative mortality rates of 3.7% and infarction rates of 9.9% have been reported,78 which are considerably higher than those associated with elective surgery. Even in patients with stable coronary artery disease, despite carefully controlled intraoperative ischemic periods and hypothermia, sensitive markers of tissue injury such as troponin T indicate that discrete necrosis occurs.79 80 Moreover, as surgeons undertake more complex and higher-risk operations, the need for better preservation methods increases. In a situation such as CABG, the administration of an agent before surgery that could enhance myocardial defenses would reduce susceptibility to focal necrosis during surgery and permit the extension of the intraoperative ischemic period. High-risk patients with poor preoperative left ventricular function, extensive coronary artery disease, or severe left ventricular hypertrophy could certainly benefit if the degree of protection were improved by invoking endogenous cellular adaptive mechanisms. The possibility that organ preservation before transplantation might be amenable to the same improved protection, as suggested by some experimental evidence,81 82 is also of significant interest. This might allow an extension of the "cold ischemic time" between harvesting and implantation, facilitating optimal matching of recipient to donor, as well as affording a potential improvement in early myocardial function.
|
What Are We Trying to Improve Upon? |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
It seems that techniques utilizing endogenous myocardial protection are suited to application in patients with unstable angina and non–Q-wave MI and in those undergoing planned procedures such as PTCA and CABG. In non-ST-elevation ACS there is a substantial risk of progression to acute MI or reinfarction and death. Development of effective medical therapies for these patients, including use of aspirin, heparin, nitrates, ß-adrenergic receptor antagonists, and calcium channel antagonists, has markedly reduced these event rates.65 The more widespread use of more effective antithrombotic agents, such as low-molecular-weight heparin,83 and antiplatelet therapy with glycoprotein IIb–IIIa inhibitors84 are likely to result in further improved outcome in these patients. Furthermore, percutaneous coronary interventions are frequently used in these patients. Periprocedural complication rates in patients with non-ST-elevation ACS undergoing PTCA are higher than those in patients with stable angina but are still acceptable in view of the overall higher risk for adverse events in these patients. The introduction of intracoronary stents has further improved both the short-term and long-term outcomes as compared with PTCA alone.85 Ongoing studies of new angioplasty balloons, stent coatings, and optimal adjunctive antithrombotic therapies are likely to improve the success rate of these procedures even more and to further reduce the risk of death or nonfatal MI.86 The potential protection conferred by pharmacological preconditioning in this setting may add to the currently available means of reducing the complications associated with these procedures and result in improved outcome for the patients but must be viewed in the context of these existing protective strategies.
Similarly, in the surgical setting, effective strategies of myocardial preservation have already been developed, including the use of various cardioplegic solutions. In general, the rationale behind the use of cardioplegic techniques includes rapid diastolic arrest, membrane stabilization, hyperosmolarity (to prevent intracellular edema), acid buffering, and hypothermia. Additional strategies such as continuous coronary perfusion, warm instead of cold cardioplegia (to avoid cold injury), and the use of blood instead of crystalloid solutions (to improve oxygen delivery) have all added to the choices available to the cardiac surgeon. The potential use of endogenous myocardial protection must be seen in the context of these pre-existing efficacious techniques.
|
How Can We Measure Our Success? |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
Any clinical trial involving the use of a pharmacological agent designed to mimic the protection of ischemic preconditioning will have to demonstrate its value in terms of relevant clinical end points such as preservation of left ventricular function, attenuation of stunning, need for inotropic/balloon support, incidence of clinically detectable MI, left ventricular failure, and periprocedural death. However, studies so far have concentrated on low-risk patients with good preprocedural status who would be expected to do well in any event. The benefit derived from ischemic or pharmacological preconditioning in this group of patients is therefore likely to be marginal. In the studies of preconditioning during coronary angioplasty, the end points used are indirect markers of myocardial ischemia, namely ST-segment shifts on ECG, pain scores, and metabolic end points such as coronary sinus lactate levels during balloon inflations. Likewise, the end points used in surgical studies so far are "blunt tools" that provide us with indirect information with respect to myocardial viability and are no substitute for direct measurement of infarct size. Measurement of total myocardial ATP content is not universally accepted as a sensitive marker of cell viability, and the concept of a "critical" level of ATP, below which cell death occurs, is now known to be incorrect.87 If it were possible to measure subcellular levels of ATP within different compartments (such as the mitochondrial fraction) and thereby assess local turnover, then more useful information might be available. More sensitive and specific markers of myocardial injury and death are now available, and there is considerable interest in the use of serum troponin T (or troponin I) assays.79 80 However, although these surrogate markers of myocardial injury have been used as a means of providing evidence for the concept of preconditioning in the human myocardium or to demonstrate the safety and tolerability of various pharmacological preconditioning agents in low-risk patients, they are by no means a substitute for hard end points of clinical outcome. It is only with direct evidence for an improved clinical outcome after ischemic and/or pharmacological preconditioning, which is more likely to be achieved in studies conducted in high-risk groups of patients, that preconditioning treatments may become a clinical reality.
|
Conclusions and the Future |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
Fifteen years of extensive research and publication of in excess of 1500 papers in the field of ischemic preconditioning have vastly extended our understanding of the mechanisms underlying the pathogenesis of ischemia-reperfusion injury. There can be little doubt that the elucidation of the pathophysiology and the cellular mechanisms of the phenomenon of ischemic preconditioning has taught us the means of protecting the myocardium in the experimental setting. Clinical studies in this field, while fraught with limitations, have pointed to the fact that the human myocardium may respond in a way similar to that seen in the experimental laboratory and may be amenable to protection by ischemic preconditioning. This evolving field however, has so far failed to provide any direct evidence that this plethora of experimental and clinical research may one day translate into a clinical reality that would ultimately benefit patients with coronary artery disease. Despite this, the knowledge gained as a result of this research has provided us with tools for protecting the myocyte and has enabled us to identify several classes of pharmacological agent that may be able to mimic the protection conferred by ischemic preconditioning. These include agents aimed at triggering the preconditioning phenomenon such as adenosine or its more selective analogues, bradykinin/angiotensin-converting enzyme inhibitors and opioids, and those that target the putative distal mediator of preconditioning (mito-KATP channels) such as nicorandil. A number of studies in routine (low-risk) patients have been performed with the aim of proving the concept of pharmacological preconditioning in humans and to establish the safety and tolerability of these agents using indirect end points to detect myocardial ischemia, small differences in myocardial viability, and extent of micronecrosis. These findings provide some basis for optimism that a beneficial and clinically detectable improvement in myocardial protection may yet be possible. However, this goal can only be achieved when carefully designed clinical studies using hard end points of clinical outcome have been undertaken in appropriate subsets of patients at short-term risk of coronary artery occlusion. These studies have as yet not been undertaken. In our opinion, whereas further research in the basic laboratory continues to identify the next steps in the signaling cascade mediating myocardial preconditioning, it is timely that large-scale trials of high-risk patients at multiple centers were performed with the currently available preconditioning-mimetic agents, with comparisons against pre-existing myocardial protective strategies. Such studies need to focus on the high-risk groups of patients outlined in this review, with particular emphasis on those subsets with features predictive of a worse outcome, who stand to gain the most benefit from additional cardioprotective strategies.88 The cohorts randomized in these studies may include patients with non-ST-elevation ACS presenting with persistent ST-segment depression on ECG, elevated serum troponin levels, or impaired left ventricular function, whether treated medically or with early revascularization. These patients must be randomized to preconditioning-mimetic agents versus placebo, in addition to standard therapy, and evaluated in terms of robust end points of clinical outcome. Similarly, high-risk patients undergoing elective revascularization procedures need to be included in studies evaluating the clinical efficacy of preconditioning-mimetic treatments in terms of reduction in periprocedural infarct size, heart failure, and mortality. It is only with demonstration of improved outcome in such large-scale studies that the past 15 years of research may translate into a clinical reality.
|
Received May 24, 2000; revision received August 14, 2000; accepted August 16, 2000.
|
References |
|---|
|
TopAbstractIntroductionDoes Preconditioning Occur in...Which Patients May Benefit?What Are We Trying...How Can We Measure...Conclusions and the FutureReferences |
|---|
1. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of ischemia cause no cumulative ATP loss or necrosis. Am J Physiol. 1986;251:H1306–H1315.
2.
Murry CE, Jennings RB, Reimer KA. Preconditioning with
ischemia: a delay of lethal cell injury in ischemic
myocardium. Circulation. 1986;74:1124–1136.
3.
Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G,
Sumeray MS. Ischemic preconditioning: present position and
future directions. Cardiovasc Res. 1998;37:21–33.
4. Sun JZ, Tang XL, Knowlton AA, Park SW, Bolli R. Late preconditioning against myocardial stunning: an endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs. J Clin Invest. 1995;95:388–403.
5. Bolli R. The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview. Basic Res Cardiol. 1996;91:57–63.[Medline] [Order article via Infotrieve]
6.
Shiki K, Hearse DJ. Preconditioning of
ischemic myocardium: reperfusion-induced
arrhythmias. Am J Physiol. 1987;253:H1470–H1476.
7.
Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac
stress protein elevation 24 hours after brief ischemia or heat
stress is associated with resistance to myocardial infarction.
Circulation. 1993;88:1264–1272.
8.
Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori
M, Kamada T, Tada M. Delayed effects of sublethal ischemia on
the acquisition of tolerance to ischemia. Circ Res. 1993;72:1293–1299.
9.
Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DA, Li
RK. Preconditioning human ventricular
cardiomyocytes with brief periods of simulated
ischemia. Cardiovasc Res. 1994;28:1285–1291.
10. Arstall MA, Zhao YZ, Hornberger L, Kennedy SP, Buchholz RA, Osathanondth R, Kelly RA. Human ventricular myocytes in vitro exhibit both early and delayed preconditioning responses to simulated ischemia. J Mol Cell Cardiol. 1998;30:1019–1025.[Medline] [Order article via Infotrieve]
11. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol. 1995;27:1349–1357.[Medline] [Order article via Infotrieve]
12.
Speechly-Dick ME, Grover GJ, Yellon DM. Does
ischemic preconditioning in the human involve protein kinase C
and the ATP-dependent K+ channel? Studies of
contractile function after simulated ischemia in an atrial in
vitro model. Circ Res. 1995;77:1030–1035.
13. Liang BT. Direct preconditioning of cardiac ventricular myocytes via adenosine A1 receptor and KATP channel. Am J Physiol. 1996;40:H1769–H1777.
14.
Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken
AH. Oral sulfonylurea hypoglycemic agents prevent ischemic
preconditioning in human myocardium.
Circulation. 1997;96:29–32.
15.
Ikonomidis JS, Shirai, Weisel RD, Derylo B, Rao V,
Whiteside CI, Mickle DA, Li RK. Preconditioning cultured human
pediatric myocytes requires adenosine and protein kinase C.
Am J Physiol. 1997;272:H1220–H1230.
16. Anzai T, Yoshikawa T, Asakura Y, Abe S, Akaishi M, Mitamura H, Handa S, Ogawa S. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarction. J Am Coll Cardiol. 1995;26:319–327.[Abstract]
17.
Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L,
Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe CH,
Braunwald E. Previous angina alters in-hospital outcome in TIMI 4: a
clinical correlate to preconditioning? Circulation. 1995;91:37–45.
18.
Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti
P, Pantoli D, Rusticali F. Prodromal angina limits infarct size: a role
for ischemic preconditioning. Circulation. 1995;91:291–297.
19. Tamura K, Tsuji H, Nishiue T, Tokunaga S, Iwasaka T. Association of preceding angina with in-hospital life-threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Am Heart J. 1997;133:297–301.[Medline] [Order article via Infotrieve]
20. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K, Ueda K. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol. 1997;30:970–975.[Abstract]
21.
Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K,
Yoo K, McCabe CH, Braunwald E. Prospective temporal analysis of
the onset of preinfarction angina versus outcome: an ancillary study in
TIMI-9B. Circulation. 1998;97:1042–1045.
22. Dana A, Yellon DM. Cardioprotection by preinfarct angina: is it ischemic preconditioning? Eur Heart J. 1998;19:367–369.
23.
Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider
AW, Maseri A. Preinfarction angina as a predictor of more rapid
coronary thrombolysis in patients with acute
myocardial infarction. N Engl J Med. 1996;334:7–12.
24. Andreotti F, Pasceri V. Ischaemic preconditioning. Lancet. 1996;348:204.[Medline] [Order article via Infotrieve]
25.
Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief
antecedent ischemia attenuates platelet-mediated thrombosis
in damaged and stenotic canine coronary arteries: role
of adenosine. Circulation. 1998;97:692–702.
26. Okazaki Y, Kodama K, Sato H, Kitakaze M, Hirayama A, Mishima M, Hori M, Inoue M. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Coll Cardiol. 1993;21:1597–1604.[Abstract]
27.
Williams DO, Bass TA, Gewirtz H, Most AS. Adaptation to
the stress of tachycardia in patients with coronary
artery disease: insight into the mechanism of the warm-up phenomenon.
Circulation. 1985;71:687–692.
28. Tzivoni D, Maybaum S. Attenuation of severity of myocardial ischemia during repeated daily ischemic episodes. J Am Coll Cardiol. 1997;30:119–124.[Abstract]
29.
Rinaldi CA, Masani ND, Linka AZ, Hall RJ. Effect of
repetitive episodes of exercise induced myocardial ischaemia on left
ventricular function in patients with chronic stable
angina: evidence for cumulative stunning or ischaemic preconditioning?
Heart. 1999;81:404–411.
30. Stewart RA, Simmonds MB, Williams MJ. Time course of "warm-up" in stable angina. Am J Cardiol. 1995;76:70–73.[Medline] [Order article via Infotrieve]
31.
Tomai F, Crea F, Danesi A, Perino M, Gaspardone A,
Ghini AS, Cascarano MT, Chiariello L, Gioffre PA. Mechanisms of the
warm-up phenomenon. Eur Heart J. 1996;17:1022–1027.
32. Dana A, Carroll R, Walker JM, Yellon DM. Exercise induced ischemia causes both early and delayed myocardial adaptation during repeated exercise: a role for adenosine? Eur Heart J. 2000;21(suppl):366. Abstract.
33. Tomai F. Exercise-induced myocardial ischemia triggers the early phase of preconditioning but not the late phase. Am J Cardiol. 1999;83:586–588.[Medline] [Order article via Infotrieve]
34. Tomai F, Crea F, Danesi A, Perino M, Gaspardone A, Ghini AS, Ruggeri G, Chiariello L, Gioffre PA. Effects of A1 adenosine receptor blockade on the warm-up phenomenon. Cardiologia. 1997;42:385–392.[Medline] [Order article via Infotrieve]
35. Kerensky RA, Franco E, Schlaifer JD, Pepine CJ, Belardinelli L. Effect of theophylline on the warm-up phenomenon. Am J Cardiol. 1999;84:1077–1080.[Medline] [Order article via Infotrieve]
36. Correa SD, Schaefer S. Blockade of KATP channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol. 1997;79:75–78.[Medline] [Order article via Infotrieve]
37.
Tomai F, Danesi A, Ghini AS, Crea F, Perino M,
Gaspardone A, Ruggeri G, Chiariello L, Gioffre PA. Effects of K(ATP)
channel blockade by glibenclamide on the warm-up phenomenon. Eur
Heart J. 1999;20:196–202.
38.
Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW,
Herrmann HC, Laskey WK. Adaptation to ischemia during
percutaneous transluminal coronary angioplasty:
clinical, hemodynamic, and metabolic
features. Circulation. 1990;82:2044–2051.
39. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578–586.[Abstract]
40. Eltchaninoff H, Cribier A, Tron C, Derumeaux G, Koning R, Hecketsweiller B, Letac B. Adaptation to myocardial ischemia during coronary angioplasty demonstrated by clinical, electrocardiographic, echocardiographic, and metabolic parameters. Am Heart J. 1997;133:490–496.[Medline] [Order article via Infotrieve]
41. Okishige K, Yamashita K, Yoshinaga H, Azegami K, Satoh T, Goseki Y, Fujii S, Ohira H, Satake S. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol. 1996;28:70–73.[Abstract]
42. Airaksinen KE, Huikuri HV. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol. 1997;29:1035–1038.[Abstract]
43. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation. 1999;99:2985–2089.
44.
Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, De
Paulis R, Chiariello L, Goiffre PA. Phentolamine prevents
adaptation to ischemia during coronary angioplasty:
role of 
-adrenergic receptors in ischemic
preconditioning. Circulation. 1997;96:2171–2177.
45.
Billinger M, Fleisch M, Eberli FR, Garachemani A, Meier
B, Seiler C. Is the development of myocardial tolerance to repeated
ischemia in humans due to preconditioning or to collateral
recruitment? J Am Coll Cardiol. 1999;33:1027–1035.
46.
Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R,
Penta de Peppo A, Goiffre PA. Ischemic preconditioning during
coronary angioplasty is prevented by glibenclamide, a selective
ATP-sensitive K+ channel blocker.
Circulation. 1994;90:700–705.
47. Saito S, Mizumura T, Takayama T, Honye J, Fukui T, Kamato T, Moriuchi M, Hibya K, Tamura Y, Ozawa Y, Kanmatsuse K, Osawa K, Ishihata F, Nakakimura H, Sakai K. Anti-ischemic effects of nicorandil during coronary angioplasty in humans. Cardiovasc Drugs Ther. 1995;9:257–263.
48.
Tomai F, Crea F, Gaspardone F, Versaci F, De Paulis R,
Polisca P, Chiariello L, Goiffre PA. Effects of
A1 adenosine receptor blockade by
bamiphylline on ischemic preconditioning during
coronary angioplasty. Eur Heart J. 1996;17:846–853.
49.
Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck
JP. Aminophylline inhibits adaptation to ischemia during
coronary angioplasty. Eur Heart J. 1996;17:539–544.
50.
Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R.
Preconditioning of human myocardium with adenosine
during coronary angioplasty. Circulation. 1997;95:2500–2507.
51.
Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS,
Ferri C, Desideri G, Chiariello L, Gioffre PA. Effects of naloxone on
myocardial ischemic preconditioning in humans. J Am
Coll Cardiol. 1999;33:1863–1869.
52.
Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R.
Bradykinin-induced preconditioning in patients undergoing
coronary angioplasty. J Am Coll Cardiol. 1999;34:639–650.
53. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Electrophysiologic characteristics of repetitive ischemic preconditioning in the pig heart. J Mol Cell Cardiol. 1996;28:1339–1347.[Medline] [Order article via Infotrieve]
54. Cohen MV, Yang X-M, Downey JM. Attenuation of S-T segment elevation during repetitive coronary occlusions truly reflects the protection of ischemic preconditioning and is not an epiphenomenon. Basic Res Cardiol. 1997;92:426–434.[Medline] [Order article via Infotrieve]
55.
Birinvcioglu M, Yang X-M, Critz SD, Cohen MV, Downey
JM. S-T segment voltage during sequential coronary occlusions
is an unreliable marker of preconditioning. Am J
Physiol. 1999;277:H2435–H2441.
56.
Sato T, Sasaki N, Seharaseyon J, O’Rourke B,
Marbán E. Selective pharmacological agents implicate
mitochondrial but not sarcolemmal K(ATP) channels in ischemic
cardioprotection. Circulation. 2000;101:2418–2423.
57. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276–277.[Medline] [Order article via Infotrieve]
58.
Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper
J, Yellon DM. Ischemic preconditioning reduces troponin-T
release in patients undergoing cardiac surgery. Heart. 1997;77:314–318.
59.
Perrault LP, Menasche P, Bel A, Dechaumaray T, Peynet
J, Mondry A, Olivero P, Emanoilravier R, Moalic JM. Ischemic
preconditioning in acute cardiac surgery: a word of caution.
J Thorac Cardiovasc Surg. 1996;112:1378–1386.
60.
Kaukoranta P, Lepojarvi MPK, Ylitalo KV, Kiviluoma KT,
Peuhkurinen KJ. Normothermic retrograde blood cardioplegia
with or without preceding ischemic preconditioning. Ann
Thorac Surg. 1997;63:1268–1274.
61.
Perrault LP, Menasche P. Preconditioning: can nature’s
shield be raised against surgical ischemic-reperfusion injury?
Ann Thorac Surg. 1999;68:1988–1994.
62.
Illes RW, Swoyer KD. Prospective, randomized clinical
study of ischemic preconditioning as an adjunct to intermittent
cold blood cardioplegia. Ann Thorac Surg. 1998;65:748–753.
63.
Li G, Chen S, Lu E, Li Y. Ischemic
preconditioning improves preservation with cold blood cardioplegia in
valve replacement patients. Eur J Cardiothorac Surg. 1999;15:653–657.
64.
Topol EJ. Acute myocardial infarction:
thrombolysis. Heart. 2000;83:122–126.
65.
Yeghiazarians Y, Braunstein JB, Askari A, Stone PH.
Unstable angina pectoris. N Engl J Med. 2000;342:101–114.
66. Baxter G, Goma F, Yellon D. Characterisation of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res Cardiol. 1997;92:159–167.[Medline] [Order article via Infotrieve]
67.
Tang X-L, Qiu Y, Sun J-Z, Park S-W, Kalya A, Bolli R.
Time-course of late preconditioning against myocardial stunning in
conscious pigs. Circ Res. 1996;79:424–434.
68.
Cohen MV, Yang XM, Downey JM. Conscious rabbits become
tolerant to multiple episodes of ischemic preconditioning.
Circ Res. 1994;74:998–1004.
69. Tsuchida A, Thompson R, Olsson RA, Downey JM. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischemic preconditioning in rabbit heart. J Mol Cell Cardiol. 1994;26:303–311.[Medline] [Order article via Infotrieve]
70.
Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the
delayed phase of myocardial protection: repetitive adenosine
A1 receptor activation maintains rabbit
myocardium in a preconditioned state. J Am Coll
Cardiol. 1998;31:1142–1149.
71. Tavers A, Middlemiss D, Louttit JB. Cardioprotection after repeated dosing with GR79236, an adenosine A1 agonist. Br J Pharmacol. 1998;124(suppl):102P. Abstract.
72.
Patel DJ, Purcell HJ, Fox KM. Cardioprotection by
opening of the K(ATP) channel in unstable angina: is this a clinical
manifestation of myocardial preconditioning? Results of a randomized
study with nicorandil: CESAR 2 investigation. Clinical European studies
in angina and revascularization. Eur
Heart J. 1999;20:51–57.
73. Dana A, Yellon DM. ATP dependent K+ channel: a novel therapeutic target in unstable angina? Eur Heart J. 1999;20:2–5.
74.
Sato T, Sasaki N, O’Rourke B, Marbán E.
Nicorandil, a potent cardioprotective agent, acts by opening
mitochondrial ATP-dependent potassium channels. J Am Coll
Cardiol. 2000;35:514–518.
75. FRISC II investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715.[Medline] [Order article via Infotrieve]
76.
Williams DO, Brauwald E, Thompson B, Sharaf BL, Buller
C, Knatterud GL. Results of percutaneous transluminal
coronary angioplasty in unstable angina and non Q-wave
myocardial infarction: observations from the TIMI IIIB Trial.
Circulation. 1996;94:2749–2755.
77. Lim R, Laskey WK. Ischemic preconditioning in unstable coronary symptoms: evidence for time dependence. J Am Coll Cardiol. 1997;30:1461–1465.[Abstract]
78. Kaiser GC, Schaff HV, Killip T. Myocardial revascularization for unstable angina pectoris. Circulation. 1989;79:160–167.
79. Mair J, Wieser C, Seibt I, Artner-Dworazak E, Furtwangler W, Waldenberger F, Balogh D, Puschendorf B. Troponin-T to diagnose myocardial infarction in bypass surgery. Lancet. 1991;337:434–435.
80. Hake U, Schmid F, Iversen S, Dahm M, Mayer E, Hafner G, Oelert H. Troponin-T: a reliable marker of perioperative myocardial infarction? Eur J Cardiothorac Surg. 1993;7:628–633.[Abstract]
81. Karck M, Rahmanian P, Haverick A. Ischemic preconditioning enhances donor heart preservation. Transplantation. 1996;62:17–22.[Medline] [Order article via Infotrieve]
82.
Kirsch M, Baufreton C, Fernandez C, Brunet S, Pasteau
F, Astier A, Loisance DY. Preconditioning with cromokalim improves
long-term myocardial preservation for heart transplantation. Ann
Thorac Surg. 1998;66:417–424.
83.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ,
Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A
comparison of low-molecular-weight heparin with unfractionated heparin
for unstable coronary artery disease: Efficacy and Safety of
Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study
Group. N Engl J Med. 1997;337:447–452.
84.
Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol
EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor
inhibition in non-ST-elevation acute coronary syndromes: early
benefit during medical treatment only, with additional protection
during percutaneous coronary intervention.
Circulation. 1999;100:2045–2048.
85.
Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP,
Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R,
Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J,
Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Raite R, Goldberg S. A
randomized comparison of coronary-stent placement and balloon
angioplasty in the treatment of coronary artery disease: Stent
Restenosis Study Investigators. N Engl J
Med. 1994;331:496–501.
86.
Bittl JA. Advances in coronary angioplasty.
N Engl J Med. 1996;335:1290–1302.
87.
Opie LH. Cardiac metabolism: emergence,
decline, and resurgence, part 2. Cardiovasc Res. 1992;26:817–830.
88.
Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang
WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW,
Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in
patients with acute coronary syndromes without persistent
ST-segment elevation: results from an international trial of 9461
patients: the PURSUIT investigators. Circulation. 2000;101:2557–2567.
This article has been cited by other articles:
 |
|
 |
|
  K. Boengler, R. Schulz, and G. Heusch Loss of cardioprotection with ageing Cardiovasc Res, July 15, 2009; 83(2): 247 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Noyan-Ashraf, M. A. Momen, K. Ban, A.-M. Sadi, Y.-Q. Zhou, A. M. Riazi, L. L. Baggio, R. M. Henkelman, M. Husain, and D. J. Drucker GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice Diabetes, April 1, 2009; 58(4): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Huang, J. Rubinstein, A. R. Prieto, L. V. Thang, and D. H. Wang Transient Receptor Potential Vanilloid Gene Deletion Exacerbates Inflammation and Atypical Cardiac Remodeling After Myocardial Infarction Hypertension, February 1, 2009; 53(2): 243 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Hart, C. Much, D. Kohler, J. Schittenhelm, I. C. Gorzolla, G. L. Stahl, and H. K. Eltzschig Use of a hanging-weight system for liver ischemic preconditioning in mice Am J Physiol Gastrointest Liver Physiol, June 1, 2008; 294(6): G1431 - G1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text]
|
|
|
|
 |
|
 I. Khaliulin, S. J. Clarke, H. Lin, J. Parker, M.-S. Suleiman, and A. P. Halestrap Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore J. Physiol., June 15, 2007; 581(3): 1147 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Burdess and D Newby Harnessing the preconditioning phenomenon: does remote organ ischaemia provide the answer? Heart, October 1, 2006; 92(10): 1367 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Inserte, D. Garcia-Dorado, V. Hernando, I. Barba, and J. Soler-Soler Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion Cardiovasc Res, May 1, 2006; 70(2): 364 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Turnbull, H.-Z. Zhou, P. M. Swigart, S. Turcato, J. S. Karliner, B. R. Conklin, P. C. Simpson, and A. J. Baker Sustained preconditioning induced by cardiac transgenesis with the tetracycline transactivator Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1103 - H1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bolli and A. Abdel-Latif No Pain, No Gain: The Useful Function of Angina Circulation, December 6, 2005; 112(23): 3541 - 3543. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Canyon and G. P. Dobson Pretreatment with an adenosine A1 receptor agonist and lidocaine: A possible alternative to myocardial ischemic preconditioning J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 371 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okada, H. Otani, Y. Wu, T. Uchiyama, S. Kyoi, R. Hattori, T. Sumida, H. Fujiwara, and H. Imamura Integrated pharmacological preconditioning and memory of cardioprotection: role of protein kinase C and phosphatidylinositol 3-kinase Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H761 - H767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barandon, P. Dufourcq, P. Costet, C. Moreau, C. Allieres, D. Daret, P. D. Santos, J.-M. D. Lamaziere, T. Couffinhal, and C. Duplaa Involvement of FrzA/sFRP-1 and the Wnt/Frizzled Pathway in Ischemic Preconditioning Circ. Res., June 24, 2005; 96(12): 1299 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Jin, E. J. Goetzl, and J. S. Karliner Sphingosine Kinase Activation Mediates Ischemic Preconditioning in Murine Heart Circulation, October 5, 2004; 110(14): 1980 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mayr, B. Metzler, Y.-L. Chung, E. McGregor, U. Mayr, H. Troy, Y. Hu, M. Leitges, O. Pachinger, J. R. Griffiths, et al. Ischemic preconditioning exaggerates cardiac damage in PKC-{delta} null mice Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H946 - H956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, E. Kodani, J. Wang, S. X. Zhang, H. Takano, X.-L. Tang, and R. Bolli Cardioprotection During the Final Stage of the Late Phase of Ischemic Preconditioning Is Mediated by Neuronal NO Synthase in Concert With Cyclooxygenase-2 Circ. Res., July 9, 2004; 95(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function Heart, April 1, 2004; 90(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Leesar, M. F. Stoddard, Y.-T. Xuan, X.-L. Tang, and R. Bolli Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans J. Am. Coll. Cardiol., August 6, 2003; 42(3): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Cai, D. J. Manalo, G. Wei, E. R. Rodriguez, K. Fox-Talbot, H. Lu, J. L. Zweier, and G. L. Semenza Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion Injury Circulation, July 8, 2003; 108(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bartling, I. Friedrich, R.-E. Silber, and A. Simm Ischemic preconditioning is not cardioprotective in senescent human myocardium Ann. Thorac. Surg., July 1, 2003; 76(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. o. Cosar and C. J. O'Connor Hibernation, Stunning, and Preconditioning: Historical Perspective, Current Concepts, Clinical Applications, and Future Implications Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 115 - 140. [Abstract] [PDF]
|
|
|
|
|
|
E J P Lamfers, T E H Hooghoudt, D P Hertzberger, A Schut, P W J Stolwijk, and F W A Verheugt Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients' characteristics, and prognosis Heart, May 1, 2003; 89(5): 496 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, Y. Guo, Y.-T. Xuan, C. J. Lowenstein, S. C. Stevenson, S. D. Prabhu, W.-J. Wu, Y. Zhu, and R. Bolli Gene Therapy With Inducible Nitric Oxide Synthase Protects Against Myocardial Infarction via a Cyclooxygenase-2-Dependent Mechanism Circ. Res., April 18, 2003; 92(7): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinmura, E. Kodani, Y. u-T. Xuan, B. Dawn, X.-L. Tang, and R. Bolli Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1183 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Przyklenk and G. Heusch Late preconditioning against myocardial stunning: Does aspirin close the "second window" of endogenous cardioprotection? J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1195 - 1197. [Full Text] [PDF]
|
|
|
|
|
|
J. Vaage and G. Valen Preconditioning and cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): S709 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Skyschally, R. Schulz, P. Gres, H.-G. Korth, and G. Heusch Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H698 - H703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text]
|
|
|
|
|
|
P. Taggart and D. M. Yellon Preconditioning and Arrhythmias Circulation, December 10, 2002; 106(24): 2999 - 3001. [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, B. Murtuza, I. A. Sammut, N. Latif, J. Jayakumar, R. T. Smolenski, Y. Kaneda, Y. Sawa, H. Matsuda, and M. H. Yacoub Heat Shock Protein 72 Enhances Manganese Superoxide Dismutase Activity During Myocardial Ischemia-Reperfusion Injury, Associated With Mitochondrial Protection and Apoptosis Reduction Circulation, September 24, 2002; 106(12_suppl_1): I-270 - I-276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bolli, K. Shinmura, X.-L. Tang, E. Kodani, Y.-T. Xuan, Y. Guo, and B. Dawn Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning Cardiovasc Res, August 15, 2002; 55(3): 506 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Strohm, M. Barancik, M.-L. von Bruehl, M. Strniskova, C. Ullmann, R. Zimmermann, and W. Schaper Transcription inhibitor actinomycin-D abolishes the cardioprotective effect of ischemic reconditioning Cardiovasc Res, August 15, 2002; 55(3): 602 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Z. Zhou, J. S. Karliner, and M. O. Gray Moderate alcohol consumption induces sustained cardiac protection by activating PKC-epsilon and Akt Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H165 - H174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Giblin, Y. Cui, L. H. Clapp, and A. Tinker Assembly Limits the Pharmacological Complexity of ATP-sensitive Potassium Channels J. Biol. Chem., April 12, 2002; 277(16): 13717 - 13723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Hampson and M. Grimaldi 12-Hydroxyeicosatetrenoate (12-HETE) Attenuates AMPA Receptor-Mediated Neurotoxicity: Evidence for a G-Protein-Coupled HETE Receptor J. Neurosci., January 1, 2002; 22(1): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Vakili, R. C. Kaplan, and D. L. Brown Sex-Based Differences in Early Mortality of Patients Undergoing Primary Angioplasty for First Acute Myocardial Infarction Circulation, December 18, 2001; 104(25): 3034 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kloner and R. B. Jennings Consequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 2 Circulation, December 18, 2001; 104(25): 3158 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz, M. V Cohen, M. Behrends, J. M Downey, and G. Heusch Signal transduction of ischemic preconditioning Cardiovasc Res, November 1, 2001; 52(2): 181 - 198. [Full Text] [PDF]
|
|
|
|
|
|
G. Heusch Nitroglycerin and Delayed Preconditioning in Humans : Yet Another New Mechanism for an Old Drug? Circulation, June 19, 2001; 103(24): 2876 - 2878. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Leesar, M. F. Stoddard, B. Dawn, V. G. Jasti, R. Masden, and R. Bolli Delayed Preconditioning-Mimetic Action of Nitroglycerin in Patients Undergoing Coronary Angioplasty Circulation, June 19, 2001; 103(24): 2935 - 2941. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||